Israele - inglese - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - ertugliflozin (l-pga) - film coated tablets - ertugliflozin (l-pga) 15 mg - ertugliflozin - steglatro is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:• as monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications.• in addition to other medicinal products for the treatment of diabetes.

Israele - inglese - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - ertugliflozin (l-pga) - film coated tablets - ertugliflozin (l-pga) 5 mg - ertugliflozin - steglatro is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:• as monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications.• in addition to other medicinal products for the treatment of diabetes.

Israele - inglese - Ministry of Health

merck sharp & dohme israel ltd - alendronate as sodium - tablets - alendronate as sodium 70 mg - alendronic acid - fosalan is indicated for the treatment of osteoporosis in postmenopausal women to prevent fractures, including those of the hip and spine (vertebral compression fractures). treatment to increase bone mass in men with osteoporosis.

Israele - inglese - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - daptomycin - lyophilized powder for solution for injection - daptomycin 500 mg/vial - daptomycin - cubicin is indicated for the treatment of the infections listed below. * complicated skin and skin structure infectionscomplicated skin and skin structure infections (csssi) caused by susceptible isolates of the following gram-positive bacteria: staphylococcus aureus (including methicillin-resistant isolates), streptococcus pyogenes, streptococcus agalactiae, streptococcus dysgalactiae subsp. equisimilis, and enterococcus faecalis (vancomycin-susceptible isolates only).* staphylococcus aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolatesstaphylococcus aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates.* combination therapy may be clinically indicated if the documented or presumed pathogens include gram negative or anaerobic organisms

Israele - inglese - Ministry of Health

merck sharp & dohme israel ltd - pembrolizumab - powder for solution for infusion - pembrolizumab 50 mg/vial - pembrolizumab - - melanoma:keytruda (pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma.- non-small cell lung cancer:• keytruda, in combination with pemetrexed and carboplatin, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (nsclc) negative for egfr or alk genomic tumor aberrations.• keytruda, in combination with carboplatin and either paclitaxel or nab-paclitaxel, is indicated for the first-line treatment of patients with metastatic squamous nsclc. • keytruda, as a single agent, is indicated for the treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors express pd-l1 [tumor proportion score (tps) ≥50%)] as determined by a validated test. patients with egfr or alk genomic tumor aberrations should have disease progression on or after platinum-containing chemotherapy and an approved therapy for these aberrations prior to receiving keytruda.• keytruda, as a single agent, is indic

Israele - inglese - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - ertugliflozin (l-pga); sitagliptin as monohydrate phosphate - film coated tablets - sitagliptin as monohydrate phosphate 100 mg; ertugliflozin (l-pga) 15 mg - sitagliptin and ertugliflozin - steglujan is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:• when metformin and/or a sulphonylurea (su) and one of the monocomponents of steglujan do not provide adequate glycaemic control• in patients already being treated with the combination of ertugliflozin and sitagliptin as separate tablets.

Israele - inglese - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - ertugliflozin (l-pga); sitagliptin as monohydrate phosphate - film coated tablets - sitagliptin as monohydrate phosphate 100 mg; ertugliflozin (l-pga) 5 mg - sitagliptin and ertugliflozin - steglujan is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:• when metformin and/or a sulphonylurea (su) and one of the monocomponents of steglujan do not provide adequate glycaemic control• in patients already being treated with the combination of ertugliflozin and sitagliptin as separate tablets.

Unione Europea - inglese - EMA (European Medicines Agency)

merck sharp and dohme b.v - sitagliptin, metformin hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - for patients with type-2 diabetes mellitus:efficib is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.efficib is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.efficib is indicated as triple combination therapy with a ppar agonist (i.e. a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a ppar agonist.efficib is also indicated as add on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dosage of insulin and metformin alone do not provide adequate glycaemic control.

Irlanda - inglese - HPRA (Health Products Regulatory Authority)

merck sharp and dohme limited - famotidine - film coated tablet - 20 milligram

Irlanda - inglese - HPRA (Health Products Regulatory Authority)

merck sharp and dohme limited - famotidine - film coated tablet - 40 milligram